computer-generated random numbers sas software version 9.4 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
computer-generated random numbers sas software version 9.4
Computer Generated Random Numbers Sas Software Version 9.4, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random+number+generation+by+sas+software+9%2E4/sas+version+9+4/10__1016_slash_s1470___2045_ascii40_25_ascii41_00286___4-8-10-10
Average 90 stars, based on 1 article reviews
Computer Generated Random Numbers Sas Software Version 9.4, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/random+number+generation+by+sas+software+9%2E4/sas+version+9+4/10__1016_slash_s1470___2045_ascii40_25_ascii41_00286___4-8-10-10
Average 90 stars, based on 1 article reviews
computer-generated random numbers sas software version 9.4 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Sequencing:Article Title: Design and rationale of the multicenter randomized clinical trial (REVERSE): Efficacy and safety of rivaroxaban in the early postoperative period for patients with bioprosthetic valve replacement or valve repair. Article Snippet: BACKGROUND Jo ur na l P re -p ro of Journal Pre-proof Rivaroxaban, a Non-vitamin K oral anticoagulant (NOAC), is extensively employed for patients at heightened risk of thrombosis, including those with non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE).. However, to date, there is a lack of robust clinical data to explore the efficacy and safety of rivaroxaban in thromboprophylaxis during the early postoperative period (<6 months) in patients following surgical bioprosthetic valve (BPV).. METHODS The REVERSE trial is a prospective, multicenter, non-inferior, randomized controlled trial enrolling a planned 250 patients in China. |